APA (7th ed.) Citation

DA, Y., W, L., M, M., A, C., L, B., B, H., . . . 3rd, B. H. (2020). A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical breast cancer, 20(2), 89. https://doi.org/10.1016/j.clbc.2019.06.005

Chicago Style (17th ed.) Citation

DA, Yardley, et al. "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer." Clinical Breast Cancer 20, no. 2 (2020): 89. https://doi.org/10.1016/j.clbc.2019.06.005.

MLA (9th ed.) Citation

DA, Yardley, et al. "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer." Clinical Breast Cancer, vol. 20, no. 2, 2020, p. 89, https://doi.org/10.1016/j.clbc.2019.06.005.